BPC 157: The peptide with big claims and scant evidence STAT RFK Jr. and the Perils of Peptides Washington Monthly FDA Targets GLP 1 and Peptide Compounding, Advertising and 'Research Use Only' Labeling In a major policy shift, the U.S. Food and Drug Administration is reconsidering restrictions on several controversial peptides, including trending compounds like BPC 157 and Melanotan II. The move comes as demand for